Cargando…
Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a receptor tyrosine kinase protein, and RET fus...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419300/ https://www.ncbi.nlm.nih.gov/pubmed/34497761 http://dx.doi.org/10.3389/fonc.2021.704084 |
_version_ | 1783748719856844800 |
---|---|
author | Takamori, Shinkichi Matsubara, Taichi Haratake, Naoki Toyokawa, Gouji Fujishita, Takatoshi Toyozawa, Ryo Ito, Kensaku Yamaguchi, Masafumi Taguchi, Kenichi Okamoto, Tatsuro Seto, Takashi |
author_facet | Takamori, Shinkichi Matsubara, Taichi Haratake, Naoki Toyokawa, Gouji Fujishita, Takatoshi Toyozawa, Ryo Ito, Kensaku Yamaguchi, Masafumi Taguchi, Kenichi Okamoto, Tatsuro Seto, Takashi |
author_sort | Takamori, Shinkichi |
collection | PubMed |
description | Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a receptor tyrosine kinase protein, and RET fusion-positive lung adenocarcinoma occurs in 1%–2% of cases. Clinical trials of multikinase inhibitors, including cabozantinib, vandetanib, sorafenib, and lenvatinib, that inhibit RET oncogene activity have shown their antitumor efficacy. Recently, RET inhibitors such as pralsetinib and selpercatinib that are specialized for RET kinase have also been developed, and their efficacy was investigated in previous clinical trials (BLU-667 and LOXO-292). In this review, we summarized the effects and adverse events of multikinase and selective RET inhibitors and the various diagnostic techniques for RET gene fusion. In the perspective part, we focused on the unsolved issues on treatment for RET fusion-positive lung cancer and future developments. |
format | Online Article Text |
id | pubmed-8419300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84193002021-09-07 Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue Takamori, Shinkichi Matsubara, Taichi Haratake, Naoki Toyokawa, Gouji Fujishita, Takatoshi Toyozawa, Ryo Ito, Kensaku Yamaguchi, Masafumi Taguchi, Kenichi Okamoto, Tatsuro Seto, Takashi Front Oncol Oncology Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a receptor tyrosine kinase protein, and RET fusion-positive lung adenocarcinoma occurs in 1%–2% of cases. Clinical trials of multikinase inhibitors, including cabozantinib, vandetanib, sorafenib, and lenvatinib, that inhibit RET oncogene activity have shown their antitumor efficacy. Recently, RET inhibitors such as pralsetinib and selpercatinib that are specialized for RET kinase have also been developed, and their efficacy was investigated in previous clinical trials (BLU-667 and LOXO-292). In this review, we summarized the effects and adverse events of multikinase and selective RET inhibitors and the various diagnostic techniques for RET gene fusion. In the perspective part, we focused on the unsolved issues on treatment for RET fusion-positive lung cancer and future developments. Frontiers Media S.A. 2021-08-23 /pmc/articles/PMC8419300/ /pubmed/34497761 http://dx.doi.org/10.3389/fonc.2021.704084 Text en Copyright © 2021 Takamori, Matsubara, Haratake, Toyokawa, Fujishita, Toyozawa, Ito, Yamaguchi, Taguchi, Okamoto and Seto https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Takamori, Shinkichi Matsubara, Taichi Haratake, Naoki Toyokawa, Gouji Fujishita, Takatoshi Toyozawa, Ryo Ito, Kensaku Yamaguchi, Masafumi Taguchi, Kenichi Okamoto, Tatsuro Seto, Takashi Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue |
title | Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue |
title_full | Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue |
title_fullStr | Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue |
title_full_unstemmed | Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue |
title_short | Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue |
title_sort | targeted therapy for ret fusion lung cancer: breakthrough and unresolved issue |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419300/ https://www.ncbi.nlm.nih.gov/pubmed/34497761 http://dx.doi.org/10.3389/fonc.2021.704084 |
work_keys_str_mv | AT takamorishinkichi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT matsubarataichi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT haratakenaoki targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT toyokawagouji targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT fujishitatakatoshi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT toyozawaryo targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT itokensaku targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT yamaguchimasafumi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT taguchikenichi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT okamototatsuro targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue AT setotakashi targetedtherapyforretfusionlungcancerbreakthroughandunresolvedissue |